logo
Plus   Neg
Share
Email

Bio-Techne Develops SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody

Bio-Techne Corp. (TECH) announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection. It is the first commercially available antibody that is produced using the VHH72 CoV-2 RBD Blocking/Neutralization clone.

Dave Eansor, President of Bio-Techne's Protein Sciences Segment, said: "This new SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is just part of a growing portfolio of tools from Bio-Techne that support SARS-CoV-2 research, diagnostics and therapeutic development."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. said it is probing into the hack of its fourth-quarter earnings report that prompted the chipmaker to release its earnings statement ahead of schedule. The company, which was scheduled to release the results after the market closed, released it before the market closing on Thursday. Google parent Alphabet decided to drop its Internet balloon project Loon that was launched with the idea of providing Internet access to rural areas and providing last mile connectivity. In a blog post, Loon CEO Alastair Westgarth said they have not found a way to get the costs low enough to build a long-term, sustainable business, despite gaining a number of interested partners along the way. American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter.
RELATED NEWS
Follow RTT